CeO2-Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals

8Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

This study is one of the first attempts to assess CeO2 nanoparticles as a nanoplatform for radiopharmaceuticals with radionuclides. The process of functionalization using a bifunctional azacrown ligand is described, and the resulting conjugates are characterized by IR and Raman spectroscopy. Their complexes with 207Bi show a high stability in medically relevant media, thus encouraging the further study of these conjugates in vivo as potential combined radiopharmaceuticals.

Cite

CITATION STYLE

APA

Khabirova, S., Aleshin, G., Plakhova, T., Zubenko, A., Shchukina, A., Fedorova, O., … Kalmykov, S. (2022). CeO2-Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals. Nanomaterials, 12(24). https://doi.org/10.3390/nano12244484

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free